Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report

Thymic carcinoma is a rare malignant tumor with a poor prognosis. No standard treatment is currently available. The present case was a 64-year-old male smoker with no symptoms referred to our hospital because of abnormal chest radiological findings. The CT study showed a tumor between the anterior m...

Full description

Bibliographic Details
Main Authors: Yoichi Nishii, Kazuki Furuhashi, Kentaro Ito, Tadashi Sakaguchi, Yuta Suzuki, Kentaro Fujiwara, Taro Yasuma, Tetsu Kobayashi, Corina N. D’Alessandro-Gabazza, Esteban C. Gabazza, Osamu Taguchi, Osamu Hataji
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Pharmaceuticals
Subjects:
pembrolizumab
thymic carcinoma
squamous cell carcinoma
lung cancer
Online Access:https://www.mdpi.com/1424-8247/15/7/889

Internet

https://www.mdpi.com/1424-8247/15/7/889

Similar Items